Chart-Typ:
Zeitraum:
| ALTERITY THERAPEUTICS LIMITED: Appendix 4C - Q4 FY25 Quarterly Cash Flow Report | Highlights Granted U.S. FDA Fast Track Designation for ATH434 to treat Multiple System Atrophy (MSA)Reported positive topline data from open-label Phase 2 clinical trial of ATH434 in MSAPresented... ► Artikel lesen |
| ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy | - ATH434 Demonstrated Clinical Benefit on the Unified MSA Rating Scale and Global Measures of Neurological Symptoms - - Neuroimaging Biomarkers Showed Target Engagement and Slowed Brain Atrophy... ► Artikel lesen |
| ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy | - Fast Track Designation highlights potential of ATH434 to address high unmet need for individuals with MSA - MELBOURNE, Australia and SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics... ► Artikel lesen |
| SurgePays Reports First Quarter 2025 Financial Results | AT&T Integration Complete; Nationwide Launch Positions Company for Most Aggressive Growth Phase to Date
Company Ships Over 250,000 SIM Cards and Secures $6 Million... ► Artikel lesen |
| Pre-market Movers: OSR Holdings, SurgePays, Beeline Holdings, Humacyte, Tenon Medical | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.45 A.M. ET).In the Green OSR Holdings, Inc. (OSRH) is up over 173% at $4.37.
SurgePays... ► Artikel lesen |
| SurgePays Reports 2024 Financial Results and Issues Revenue Guidance of Over $200 Million in Next 12 Months | Completed AT&T integration positions company for its most aggressive growth phase to date with projected positive cash flow from operations in 2025
BARTLETT, Tenn.... ► Artikel lesen |
| Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update | Enrollment Complete in Cohorts 1 and 2 of MyPEAK-1 Phase 1b/2 Trial of TN-201 for MYBPC3-associated HCM; Positive DSMB Safety Review Enables Enrollment of Expansion Cohorts Cohort 1 of RIDGE-1 Phase... ► Artikel lesen |
| Tenaya Therapeutics, Inc.: Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed | Enrollment in Both Dose Cohorts of the MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 for Hypertrophic Cardiomyopathy (HCM) Complete; Follow-up Data from Cohort 1 and Initial Data from Cohort 2 Expected... ► Artikel lesen |
| Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LIMINATUS PHARMA INC finden Sie auf Wallstreet Online.